双重COX/LOX抑制剂设计的最新进展 (2020-2024):建立"炎症四项规则"
Filippos Panteleimon Chatzipieris1, Errikos Petsas1, George Lambrinidis2
1Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
Life (Basel, Switzerland)
|January 28, 2026
概括
本综述强调了最近在理解酸通路方面取得的进展,重点关注用于炎症的循环氧化酶-2 (COX-2) 和5-脂氧化酶 (5-LOX) 双重抑制剂. "炎症的四项规则"概述了强大的双重抑制的关键结构特征.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 阿拉基酸通路对于前列腺素和白血类炎症调解剂至关重要.
- 这种途径的放松调节有助于疾病,包括心血管疾病,代谢障碍和癌症.
- 循环氧基酶-2 (COX-2) 和5-脂氧基酶 (5-LOX) 是该途径中的关键酶和重要的治疗点.
研究的目的:
- 审查最近 (2020-2024) 关于阿拉基酸通路的证据.
- 检查炎症中COX-2和5-LOX酶的结构,功能和活性部位.
- 为了确定COX-2和5-LOX的强有力的双重抑制剂.
主要方法:
- 文献综述侧重于2020-2024年的研究.
- 对双重COX-2/5-LOX抑制剂的体外和体内实验数据的分析.
- 结构-活动关系 (SAR) 分析以确定抑制的关键结构特征.
主要成果:
- 最近的研究使人们更好地了解了酸通路在炎症中的作用.
- 针对COX-2和5-LOX的双抑制剂显示出显著的治疗潜力.
- SAR分析确定了强大的双重抑制的四个关键结构特征,称为"炎症的四项规则".
结论:
- 同时针对COX-2和5-LOX提供了一种有前途的策略来管理炎症疾病.
- "炎症的四项规则"为设计新型双重抑制剂提供了一个框架.
- 对这些双重抑制剂的进一步研究可能会导致与炎症相关的疾病的新疗法.
相关概念视频
Inflammation
Overview
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Inflammation: Introduction
Inflammation is a fundamental, protective biological response of vascularized tissues to cellular injury, infection, or harmful stimuli. Its primary function is to eliminate the initial cause of injury, clear necrotic cells and damaged tissue, and initiate the necessary repair processes.Cardinal SignsAcute inflammation presents with classic signs. Redness results from vasodilation and increased blood flow. Heat is due to increased metabolism and circulation. Swelling results from the...
Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...


